Thioridazine: resurrection as an antimicrobial agent?
Identifieur interne : 006392 ( Main/Exploration ); précédent : 006391; suivant : 006393Thioridazine: resurrection as an antimicrobial agent?
Auteurs : H K R. ThanacoodySource :
- British Journal of Clinical Pharmacology [ 0306-5251 ] ; 2007.
Abstract
The emergence of multiresistant bacterial strains and the continuing burden of infectious disease globally point to the urgent need for novel affordable antimicrobial drugs. Thioridazine is a phenothiazine antipsychotic drug with well-recognized antimicrobial activity, but this property has not been harnessed for clinical use as a result of its central nervous system and cardiac side-effects. The cardiotoxicity of thioridazine has recently been shown to be structurally specific at a molecular level, whereas its antimicrobial properties are shared by a number of phenothiazine analogues. This raises the possibility that its enantiomers or its inactive metabolite, the ring sulphoxide, may act as a lead compound in the future development of antimicrobial drugs to face the new challenges in infectious disease.
Url:
DOI: 10.1111/j.1365-2125.2007.03021.x
PubMed: 17764469
PubMed Central: 2203271
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 002D55
- to stream Pmc, to step Curation: 002D54
- to stream Pmc, to step Checkpoint: 002A58
- to stream Ncbi, to step Merge: 000453
- to stream Ncbi, to step Curation: 000453
- to stream Ncbi, to step Checkpoint: 000453
- to stream Main, to step Merge: 006495
- to stream Main, to step Curation: 006392
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Thioridazine: resurrection as an antimicrobial agent?</title><author><name sortKey="Thanacoody, H K R" sort="Thanacoody, H K R" uniqKey="Thanacoody H" first="H K R" last="Thanacoody">H K R. Thanacoody</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">17764469</idno><idno type="pmc">2203271</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2203271</idno><idno type="RBID">PMC:2203271</idno><idno type="doi">10.1111/j.1365-2125.2007.03021.x</idno><date when="2007">2007</date><idno type="wicri:Area/Pmc/Corpus">002D55</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002D55</idno><idno type="wicri:Area/Pmc/Curation">002D54</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002D54</idno><idno type="wicri:Area/Pmc/Checkpoint">002A58</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002A58</idno><idno type="wicri:Area/Ncbi/Merge">000453</idno><idno type="wicri:Area/Ncbi/Curation">000453</idno><idno type="wicri:Area/Ncbi/Checkpoint">000453</idno><idno type="wicri:doubleKey">0306-5251:2007:Thanacoody H:thioridazine:resurrection:as</idno><idno type="wicri:Area/Main/Merge">006495</idno><idno type="wicri:Area/Main/Curation">006392</idno><idno type="wicri:Area/Main/Exploration">006392</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Thioridazine: resurrection as an antimicrobial agent?</title><author><name sortKey="Thanacoody, H K R" sort="Thanacoody, H K R" uniqKey="Thanacoody H" first="H K R" last="Thanacoody">H K R. Thanacoody</name></author></analytic><series><title level="j">British Journal of Clinical Pharmacology</title><idno type="ISSN">0306-5251</idno><idno type="eISSN">1365-2125</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The emergence of multiresistant bacterial strains and the continuing burden of infectious disease globally point to the urgent need for novel affordable antimicrobial drugs. Thioridazine is a phenothiazine antipsychotic drug with well-recognized antimicrobial activity, but this property has not been harnessed for clinical use as a result of its central nervous system and cardiac side-effects. The cardiotoxicity of thioridazine has recently been shown to be structurally specific at a molecular level, whereas its antimicrobial properties are shared by a number of phenothiazine analogues. This raises the possibility that its enantiomers or its inactive metabolite, the ring sulphoxide, may act as a lead compound in the future development of antimicrobial drugs to face the new challenges in infectious disease.</p></div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Thanacoody, H K R" sort="Thanacoody, H K R" uniqKey="Thanacoody H" first="H K R" last="Thanacoody">H K R. Thanacoody</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006392 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006392 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:2203271
|texte= Thioridazine: resurrection as an antimicrobial agent?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17764469" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |